From our survey

What treatment-resistant depression means, explained for St. Louis

"Treatment-resistant" is a phrase that can land like a door closing. You hear it in a doctor's office, or you read it in a patient portal, and it sounds like your brain has been graded and failed.

It does not mean that. This explainer walks through what the term actually describes, why it happens, and what clinicians in the St. Louis area typically consider next. It also shares a finding from our own survey that suggests the experience behind the label is far more common than most people think.

A plain definition

Clinicians generally use "treatment-resistant depression" when major depression has stayed significant through two or more antidepressants in the current episode, with each given enough dose and enough weeks to work. Definitions vary a little between guidelines and insurers, but that two-trial idea is the common core.

Notice what the definition measures. It is about how the illness responded to specific treatments. It says nothing about effort, willpower, or whether you tried hard enough. Depression is not one single condition with one single fix, and different brains respond to different approaches.

How common is the experience?

Our commissioned survey of 443 Midwest adults, Missourians and Illinoisans included, asked if standard medication had failed to loosen depression, anxiety, or PTSD for the respondent or someone close. The tally: 72 percent, a little under three in four.

For 37 percent the experience was their own, and 22 percent had watched it only in someone close. Another 13 percent had lived it and also watched it in someone close. More than a quarter, 28 percent, said none of it applied.

One caution. Our question was broader than the clinical definition, since it included anxiety and PTSD and relied on people's own sense that the medicine did not help. The figures themselves come from the final, validated data. Even so, the message is that stalled treatment is a mainstream experience, not a rare one.

Why the first medications sometimes do not work

There are several reasons a clinician will consider before using the term, and some of them are fixable:

• Dose or duration. Antidepressants usually need weeks to reach full strength. A trial that was too short or too low may not count.
• Side effects. Many people stop a medication because of how it makes them feel. That is common and worth saying out loud to your doctor.
• A different diagnosis. Sometimes what looks like ordinary depression is part of another condition, which changes what treatment makes sense.
• Other health factors. Sleep problems, other medical conditions, substance use, or ongoing stress can all make depression harder to lift.
• Biology. Some people simply do not respond to the way common antidepressants work, even when everything else is right.

What usually comes after

The range of options is wider than many people realize. For a given person, a clinician might weigh:

• Changing to a different antidepressant, or adding a second medication to strengthen the first.
• Adding or intensifying psychotherapy.
• Transcranial magnetic stimulation, or TMS, a drug-free treatment using magnetic pulses.
• Esketamine nasal spray, sold as Spravato, approved for adults whose depression has resisted treatment.

Most people have not heard of several of these. Among our respondents, the name Spravato was unfamiliar to 73 percent, and fewer than one in ten could say what it was. Only about a quarter knew what TMS is. A treatment you have never heard of cannot be something you ask about, which is why the explaining matters. This Spravato explainer covers the basics.

Esketamine and ketamine are not the same thing

Because the names are close, people often mix them up. Esketamine, marketed as Spravato, carries FDA approval as a nasal spray. It is used under direct supervision in a certified healthcare setting, followed by a period of monitoring before the patient leaves. Patients cannot drive after a session on the day they receive it.

Ketamine for depression, whether by IV infusion in a clinic or in forms prescribed for use at home, is off-label, meaning ketamine itself does not carry FDA approval for depression. At-home versions in particular come with less oversight. They are different decisions with different safeguards.

Where respondents would begin

Their primary care doctor would get the first call from 56 percent. Almost a quarter would go straight to a psychiatrist. Relatively few would try to figure it out online on their own.

Your primary care doctor already has your history, can review which trials you have had, and can refer you onward. In a metro as spread out as St. Louis, with care split across the city, the county, and the Metro East, a referral from a doctor who knows local specialists saves wrong turns.

A few questions worth asking

• Do my past medication trials meet the definition of treatment-resistant depression?
• Were any of those trials too short or too low a dose to count?
• Is there anything else going on, medically, that could be making this harder?
• What options are realistic for me next, and why?
• If I need a specialist, who would you send me to?

What the label is really for

At its best, "treatment-resistant" is a signpost rather than a sentence. To your care team, it says the standard opening moves are used up and a wider view is due. Insurers often use the same label when deciding whether to pay for more specialized treatment, which is one practical reason it matters to have your history documented clearly.

No article can pick your treatment; you and a clinician with your full history do that together. But you can walk into that conversation knowing the term, knowing you are far from alone, and knowing the list of options does not end where your first prescriptions did.

Thoughts of suicide, or a fear that you might hurt yourself, call for help today rather than at your next visit. Contact the Suicide and Crisis Lifeline through 988, voice or text, whatever the hour; veterans can press 1, and trained counselors are ready for exactly this moment.

Methodology

Pollfish carried the survey to its consumer panel members, and by June 23, 2026, 443 people had completed it. Participants ranged from 18 to 64 and lived in Nebraska, Ohio, Missouri, Kansas, Iowa, Minnesota, Wisconsin, Indiana, Illinois, or Oklahoma. Only top-line percentages are reported, all of them validated and final. Every cost was paid by the publisher, which commissioned the study. This article is educational and is not medical advice.